David de Graaf

Chief Executive Officer at Abcuro, Inc.

David de Graaf

David de Graaf

Chief Executive Officer at Abcuro, Inc.

Overview
Career Highlights

Abcuro, Inc.
Selventa, Inc.
Comet Therapeutics

RelSci Relationships

4357

Number of Boards

3

Contact Data
Trying to get in touch with David de Graaf? Subscribe today to access their professional contact information and receive a one time promotion of free Contact Data credits!
Relationships
RelSci Relationships are individuals David de Graaf likely has professional access to. A relationship does not necessarily indicate a personal connection.

Scientific Founder at Syntimmune, Inc.

Relationship likelihood: Strong

President, Chief Executive Officer & Director at Arch Oncology, Inc.

Relationship likelihood: Strong

Director at Chinook Therapeutics, Inc.

Relationship likelihood: Strong

Founder at Apple Tree Partners

Relationship likelihood: Strong

Chief Executive Officer & Director at Mediar Therapeutics, Inc.

Relationship likelihood: Strong

Chief Executive Officer at Verseau Therapeutics, Inc.

Relationship likelihood: Strong

Partner, Innovation Fund at Mass General Brigham, Inc.

Relationship likelihood: Strong

Co-Founder at Frontier Medicines

Relationship likelihood: Strong

Chief Executive Officer at MorphoSys AG

Relationship likelihood: Strong

Director at Syntimmune, Inc.

Relationship likelihood: Strong

Paths to David de Graaf
Potential Connections via
Relationship Science
You
David de Graaf
Chief Executive Officer at Abcuro, Inc.
Education
PhD Mammalian Genetics

UIC is a major research university offering the cultural, business and entertainment opportunities you can only find in a world-class city. As one of the top 200 research-funded institutions in the world, UIC faculty discover the things that others teach. Choose from 15 academic colleges including the UIC College of Medicine-the largest in the nation-which educates one in six Illinois physicians. With nearly 2,574 instructional faculty members, there is one faculty member to every 11 students, which allows for a more personal learning experience. What's more, 75 percent of tenured faculty members teach undergraduate courses and 83 percent of full-time instructional faculty have earned a PhD or equivalent. But it's not all work and no play at UIC... Our 16,911 undergrads and 10,669 graduate and professional students make up one of the most diverse student bodies in the United States. Whether living in residence halls, near campus or commuting, you'll find there's always something interesting going on, from social events, clubs, sororities and fraternities, to two state-of-the-art fitness centers, and more-not to mention everything Chicago has to offer just minutes away. And at UIC, we take our sports seriously. The UIC Flames compete in 18 NCAA Division 1 sports and have won a total of 38 conference championships. There's a wide range of intramural teams and sports clubs for students to join.

MS Evolutionary Genetics

Hogeschool Utrecht operates as a College or University. It provides exchange, master and bachelor programmes. The firm offers education programmes for students aged from 17 till 67 years. The company is headquartered in Utrecht, the Netherlands.

Career History
Chief Executive Officer
2021 - Current

Abcuro, Inc. develops bio-therapeutics for the treatment of autoimmunity and cancer. the company was founded in 2015 and is headquartered in Newton, MA.

Professional
Tenure Unconfirmed

AstraZeneca Plc is a holding company, which engages in the research, development, and manufacture of pharmaceutical products. Its pipeline are used for the following therapy areas: oncology, cardiovascular, renal, metabolism, and respiratory. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.

President & Chief Executive Officer
2010 - Prior

Selventa, Inc. develops new approaches for the understanding and treatment of diseases. It focuses on elucidating the complexity of biology for the development of safe and effective therapeutics and molecular diagnostics. The company was founded in 2002 by Keith O. Elliston and Noubar B. Afeyan and is headquartered in Cambridge, MA.

Transactions
Details Hidden

Syntimmune, Inc. raised money in a private placement transaction

Details Hidden

Selventa, Inc. raised money in a private placement transaction

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by David de Graaf. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of David de Graaf's profile does not indicate a business or promotional relationship of any kind between RelSci and David de Graaf.